These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31139575)

  • 1. Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular
    Rienksma RA; Schaap PJ; Martins Dos Santos VAP; Suarez-Diez M
    Front Cell Infect Microbiol; 2019; 9():144. PubMed ID: 31139575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
    Lechartier B; Hartkoorn RC; Cole ST
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5790-3. PubMed ID: 22926573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
    Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
    Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro chemotherapeutic combinations against isoniazid-resistant Mycobacterium tuberculosis and Mycobacterium fortuitum.
    Goldstein E; Eagle MC; LaCasse ML
    Appl Microbiol; 1971 Sep; 22(3):329-33. PubMed ID: 4330314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the Metabolic State of
    Rienksma RA; Schaap PJ; Martins Dos Santos VAP; Suarez-Diez M
    Front Cell Infect Microbiol; 2018; 8():264. PubMed ID: 30123778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.
    Makarov V; Manina G; Mikusova K; Möllmann U; Ryabova O; Saint-Joanis B; Dhar N; Pasca MR; Buroni S; Lucarelli AP; Milano A; De Rossi E; Belanova M; Bobovska A; Dianiskova P; Kordulakova J; Sala C; Fullam E; Schneider P; McKinney JD; Brodin P; Christophe T; Waddell S; Butcher P; Albrethsen J; Rosenkrands I; Brosch R; Nandi V; Bharath S; Gaonkar S; Shandil RK; Balasubramanian V; Balganesh T; Tyagi S; Grosset J; Riccardi G; Cole ST
    Science; 2009 May; 324(5928):801-4. PubMed ID: 19299584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Components of monitoring drug resistance of tuberculosis agent in the evaluation of effectiveness of the national tuberculosis control program].
    Popov SA; Dorozhkova IR; Medvedeva IM
    Probl Tuberk; 2001; (2):18-20. PubMed ID: 11490457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on the endogenous metabolism of mycobacteria. 2. On the influence of enzyme inhibitors and effective antitubercular substances on 32 P-incorporation].
    Iwainsky H; Reutgen H; Kalich R
    Z Naturforsch B; 1968 Feb; 23(2):211-6. PubMed ID: 4385975
    [No Abstract]   [Full Text] [Related]  

  • 10. The susceptibility of mycobacteria to rifamide and rifampicin.
    Clark J; Wallace A
    Tubercle; 1967 Jun; 48(2):144-8. PubMed ID: 4293697
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug sensitivity of atypical Mycobacteria isolated from patients to antitubercular agents of the first and second order].
    Makarevich NM; Rudoĭ NM
    Antibiotiki; 1971 Feb; 16(2):149-52. PubMed ID: 4326726
    [No Abstract]   [Full Text] [Related]  

  • 13. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
    Genestet C; Bernard-Barret F; Hodille E; Ginevra C; Ader F; Goutelle S; Lina G; Dumitrescu O;
    Tuberculosis (Edinb); 2018 Jul; 111():67-70. PubMed ID: 30029917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline reprograms central metabolism to reveal glycolytic vulnerability in Mycobacterium tuberculosis.
    Mackenzie JS; Lamprecht DA; Asmal R; Adamson JH; Borah K; Beste DJV; Lee BS; Pethe K; Rousseau S; Krieger I; Sacchettini JC; Glasgow JN; Steyn AJC
    Nat Commun; 2020 Nov; 11(1):6092. PubMed ID: 33257709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioenergetic Heterogeneity in Mycobacterium tuberculosis Residing in Different Subcellular Niches.
    Akela AK; Kumar A
    mBio; 2021 Jun; 12(3):e0108821. PubMed ID: 34060333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of radiation on microbiologic characteristics of M tuberculosis.
    Zack MB; Stottmeier K; Berg G; Kazemi H
    Chest; 1974 Sep; 66(3):240-3. PubMed ID: 4213816
    [No Abstract]   [Full Text] [Related]  

  • 17. Improvement of drg-sensitivity tests on tubercle bacilli.
    Leat JL; Marks J
    Tubercle; 1970 Mar; 51(1):68-75. PubMed ID: 4099827
    [No Abstract]   [Full Text] [Related]  

  • 18. A katG S315T or an ahpC promoter mutation mediate Mycobacterium tuberculosis resistance to 2-thiophen carboxylic acid hydrazide, an inhibitor resembling the anti-tubercular drugs Isoniazid and Ethionamide.
    Franceschelli JJ; Belardinelli JM; Tong P; Loftus B; Recio-Balsells A; Labadié GR; Gordon SV; Morbidoni HR
    Tuberculosis (Edinb); 2018 Sep; 112():69-78. PubMed ID: 30205971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversion of antibiotic resistance in
    Blondiaux N; Moune M; Desroses M; Frita R; Flipo M; Mathys V; Soetaert K; Kiass M; Delorme V; Djaout K; Trebosc V; Kemmer C; Wintjens R; Wohlkönig A; Antoine R; Huot L; Hot D; Coscolla M; Feldmann J; Gagneux S; Locht C; Brodin P; Gitzinger M; Déprez B; Willand N; Baulard AR
    Science; 2017 Mar; 355(6330):1206-1211. PubMed ID: 28302858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of mycobacterial NADH pyrophosphatase isoforms reveals a novel mechanism for isoniazid and ethionamide inactivation.
    Wang XD; Gu J; Wang T; Bi LJ; Zhang ZP; Cui ZQ; Wei HP; Deng JY; Zhang XE
    Mol Microbiol; 2011 Dec; 82(6):1375-91. PubMed ID: 22026918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.